PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm
Early phase 1 study registered on ClinicalTrials.gov. Condition: Self Harm. Interventions listed: Psilocybin 5 mg with cognitive behavioural therapy intervention; Placebo with cognitive behavioural therapy intervention. Lead sponsor: Imperial College London. Sites in: United Kingdom (1 site).
Trial listings come from public registries. Taking part is up to the study team, who will check your eligibility. Recruitment status can change at any time, so check the registry record first. See also: UK psilocybin trials and is psychedelic therapy legal in the UK?
- Type
- Recruiting trial
- Location
- London, United Kingdom
- Status
- Recruiting (ClinicalTrials.gov)
- Registry
- ClinicalTrials.gov · NCT06798636
- Sponsor
- Imperial College London
- Condition
- Self Harm
- Website
- https://clinicaltrials.gov/study/NCT06798636
- Source
- https://clinicaltrials.gov/study/NCT06798636
- Last verified
- 23 October 2026
About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.
Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.
Follow access news each week
New trials, approvals and access routes, UK and Europe first.
Subscribe free →